SentiSense Logo

SentiSense

Ctrl+K

55% OFF

Quick tip: Press

K

to search stocks

A

AMGN

Amgen Inc.

$369.53

+1.93 (+0.53%)

Summary

Stories

News

Metrics

Fundamentals

Recent News

Filter:

Showing 18 of 18 articles

Korea Investment CORP Sells 22,072 Shares of Amgen Inc. $AMGN - MarketBeat

Unknown

10 hours ago

Negative

Friday Wyckoff scan — market went almost fully neutral after the selloff

Unknown

1 day ago

Neutral

How long after final interview to hear back at Amgen

Unknown

2 days ago

Neutral

I scanned 213 US stocks for institutional buying patterns today, here's what showed up

Unknown

2 days ago

Neutral

Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report? - Yahoo! Finance Canada

Unknown

3 days ago

Positive

QQQ, AMGN, CRWD, MELI: ETF Outflow Alert - Nasdaq

Unknown

3 days ago

Neutral

BAX Antibody Market Set for Explosive Growth | AbbVie • Amgen • Bristol-Myers Squibb - openPR.com

Unknown

3 days ago

Positive

Cytokines Market Global Forecast 2026-2032: Precise Treatments, Strategic Partnerships, and Supply Chain Resilience Fueling the $95+ Billion Market

GlobeNewswire Inc.

3 days ago

Positive

News thumbnail

Anyone familiar with current Amgen hiring timelines? (Ghosted after HM interview, Workday says "In consideration")

Unknown

3 days ago

Neutral

AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND

Benzinga

4 days ago

Positive

News thumbnail

New Additions for 2026

Unknown

4 days ago

Neutral

Struggling with new position, desperately need advice

Unknown

4 days ago

Neutral

My Official $SCHD Q1 Payout Estimate drops later today! 💰 Before I reveal it… what do you think $SCHD Q1 dividend growth will come in at? Here’s all the raises and cuts we’re working with right now👇 $SCHD Q1 2026 Dividend Growth Update As of Mar 4, 2026 EX DIVIDEND: 3/25 PA

Unknown

4 days ago

Neutral

GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - Clinical Trials Exploring GLP-1 Role in NAFLD and NASH Unlock Future Opportunities

GlobeNewswire Inc.

4 days ago

Positive

News thumbnail

2026 ASCO GU Update

Unknown

5 days ago

Neutral

AAPL, AA, BKR, and AMGN are among the top stocks for momentum, says Oppenheimer - Seeking Alpha

Seeking Alpha

6 days ago

Positive

A Couple's Financial Manifesto, Revisited

The Motley Fool

6 days ago

Neutral

News thumbnail

Auto rejected at Amgen despite meeting every qualification

Unknown

6 days ago

Neutral

Company Profile

Symbol

AMGN


Market Cap

$199.20B


IPO Date

Jun 17, 1983


CEO

--


Employees

31,500


Sector

--


Industry

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)


Country

United States


Exchange

--

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Read More

Similar Stocks

GILD

Gilead Sciences, Inc.

$143.93

-0.83%

REGN

Regeneron Pharmaceuticals, Inc.

$759.86

-0.66%

ABBV

AbbVie Inc.

$230.11

-0.96%

LLY

Eli Lilly and Company

$990.33

+0.72%

BIIB

Biogen Inc.

$184.87

-1.71%

SentiSense Logo

SentiSense

Sense what the market is doing.

© 2026 Compass AI Data Services, LLC. All rights reserved.


Important Disclaimer: Compass AI Data Services, LLC provides market information, sentiment analysis, and data intelligence. We do not provide investment advice, recommendations, or financial guidance. All information is for informational purposes only. Users are solely responsible for their own investment decisions. Always consult a licensed financial advisor before making investment decisions.

Cookie Preferences

We use cookies to enhance your experience and analyze site traffic. Privacy Policy